Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer; [Akciǧer kanserli hastalarin aǧrilarinin tedavisinde transdermal fentanil ve yavaş salinimli morfinin karşilaş tirilmasi]

Simple item page
dc.contributor.authorÖztürk T.
dc.contributor.authorKaradibak K.
dc.contributor.authorÇatal D.
dc.contributor.authorÇakan A.
dc.contributor.authorTugsavul F.
dc.contributor.authorÇirak K.
dc.date.accessioned2024-07-22T08:22:21Z
dc.date.available2024-07-22T08:22:21Z
dc.date.issued2008
dc.description.abstractComparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer AIM: The aim of this randomized and controlled trial was to evaluate the analgesic efficacy of trans-dermal fentanyl (TDF) and sustained-release oral morphine (SRM) primarily and their side effects secondarily, in patients with chronic lung cancer-related pain. MATERIAL-METHODS: According to three step analgesic guidelines recommended by the World Health Organization, 50 chronic lung cancer patients requiring third line therapy were enrolled and received either TDF patch (Grup F, n=25) or SRM per orally (Grup M, n=25) for 15 days. Patients were assessed in view to numeric rating scale of their pain, as well as the drugs' side effects like constipation, nausea-vomiting, urinary retention and urticaria, hypoventilation. RESULTS: Pain scores were similar for both groups at the beginning (p>0.05). While significantly lower pain scores were achieved on the 7th and 15th days compared to those of initial values in Group F and Group M patients (p<0.001); these decreases did not reach statistical significance between the groups (p>0.05). Compared to Group M, constipation was significantly lower in Group F (14 patients and 64% vs. 6 patients and 27%, respectively) (p=0.03). However, the frequencies of nausea-vomiting, urinary retention and urticaria were different between the groups (p>0.5). None of the patients developed hypoventilation. CONCLUSION: Both TDF and SRM are safe and effective analgesics for the management of chronic cancer pain. However, TDF is associated with significantly less constipation rate than that of with SRM.
dc.identifier.issn13000012
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19044
dc.language.isoTurkish
dc.subjectAdministration, Cutaneous
dc.subjectAnalgesics, Opioid
dc.subjectChronic Disease
dc.subjectDelayed-Action Preparations
dc.subjectFemale
dc.subjectFentanyl
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMorphine
dc.subjectPain
dc.subjectTreatment Outcome
dc.subjectfentanyl
dc.subjectmorphine
dc.subjectnarcotic analgesic agent
dc.subjectarticle
dc.subjectchronic disease
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdelayed release formulation
dc.subjectfemale
dc.subjecthuman
dc.subjectintradermal drug administration
dc.subjectlung tumor
dc.subjectmale
dc.subjectmiddle aged
dc.subjectpain
dc.subjectrandomized controlled trial
dc.subjecttreatment outcome
dc.titleComparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer; [Akciǧer kanserli hastalarin aǧrilarinin tedavisinde transdermal fentanil ve yavaş salinimli morfinin karşilaş tirilmasi]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize